Telix Pharmaceuticals (TLX) Operating Leases (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Operating Leases for 3 consecutive years, with $62.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Leases rose 1066.11% year-over-year to $62.1 million; the TTM figure through Dec 2025 stood at $62.1 million (up 1066.11% YoY), while the FY2025 annual figure was $62.1 million, up 1131.3% from the prior year.
• Operating Leases rose to $62.1 million in Q4 2025 per TLX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $62.1 million in Q4 2025 and bottomed at $5.0 million in Q4 2023.
• Historically, Operating Leases has averaged $24.1 million across 3 years, with a median of $5.3 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases climbed 6.53% — and 2025, when it soared 1066.11%.
• Telix Pharmaceuticals' Operating Leases stood at $5.0 million in 2023, then gained by 6.53% to $5.3 million in 2024, then jumped by 1066.11% to $62.1 million in 2025.
• Business Quant data shows TLX's Operating Leases at $62.1 million in Q4 2025, $5.3 million in Q4 2024, and $5.0 million in Q4 2023.